Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

BMC Cancer

Jianping Wang⁴  Lei Wang⁴  Zihuan Yang¹  Xinjuan Fan¹  Jizheng Li²  Jintuan Huang²  Hao Chen²  Lijun Huo³  Yang Bai²  Zuli Yang² 

[1]Gastrointestinal Institute, Sun Yat-Sen University Guangzhou, Guangzhou, P.R. China

[2]Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal and Anal Hospital), Sun Yat-Sen University Guangzhou, Guangzhou, P.R. China

[3]Department of Ophthalmology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-Sen University Guangzhou, Guangzhou, P.R. China

[4]Department of Colon & Rectum Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal and Anal Hospital), Sun Yat-Sen University Guangzhou, 26 YuancunErheng Road, Guangzhou, 510655, P.R China

关键词: Disease free survival;    Overall survival;    Prognosis;    Proliferation;    A disintegrin and metalloprotease 8 (ADAM8);    Colorectal cancer;   

Others  :  1125236
DOI  :  10.1186/1471-2407-14-568

 received in 2013-11-12, accepted in 2014-07-30,  发布年份 2014

【 摘 要 】

Background

A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim of this study was to investigate the expression and function of ADAM8 in CRC.

Methods

Expression level of ADAM8 in CRC was evaluated by quantitative RT-PCR, western blot and immunohistochemical staining analysis. The role of ADAM8 in colorectal carcinogenesis was evaluated by in vitro assays. The correlations between ADAM8 status and clinicopathological features including survival were analyzed.

Results

ADAM8 was highly expressed in CRC tissues compared with adjacent normal tissues. Knockdown of ADAM8 in two CRC cell lines resulted in reduced cellular growth and proliferation, and increased apoptosis. Immunohistochemistry analysis showed no significant correlations of ADAM8 protein expression with clinicopathologic features. Survival analysis indicated that patients with ADAM8-positive tumors had worse 5-year overall survival (OS, p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors. Multivariate analysis indicated ADAM8 expression was an independent prognostic factor for both OS and DFS (both p< 0.001). Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p< 0.05). The 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05).

Conclusions

Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.

【 授权许可】

   
2014 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Yang ZL, Wang JP, Wang L, Dong WG, Huang YH, Qin JZ, Zhan WH: Multivariate regression analysis of prognostic factors in colorectal cancer. Chin-Ger J Clin Oncol 2003, 2(3):44-51.
• [2]Popat S, Hubner R, Houlston RS: Systematic review of micro-satellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.
• [3]Kelley RK, Wang G, Venook AP: Biomarker Use in Colorectal Cancer Therapy. J Natl Compr Canc Netw 2011, 9(11):1293-1302.
• [4]Yokota T: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 2012, 12(2):163-171.
• [5]Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010, 127(2):367-380.
• [6]Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW: Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD156): implications for neuronglia interactions during neurodegeneration. J Neurosci 2000, 20:7964-7971.
• [7]Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC: The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis 2007, 25:665-674.
• [8]Dijkstra A, Postma DS, Noordhoek JA, Lodewijk ME, Kauffman HF, ten Hacken NH, Timens W: Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung. Virchows Arch 2009, 454:441-449.
• [9]Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004, 10:8363-8370.
• [10]Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 2007, 11(5):1162-1174.
• [11]Roemer A, Schwettmann L, Jung M, Stephan C, Roigas J, Kristiansen G, Loening SA, Lichtinghagen R, Jung K: The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol 2004, 172:2162-2166.
• [12]Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, Dietel M, Jung K, Kristiansen G: ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch 2006, 449(6):628-636.
• [13]Zhang Y, Tan YF, Jiang C, Zhang K, Zha TZ, Zhang M: High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 2013, 19(1):79-88.
• [14]Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE: ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med 2014, 6(2):278-294.
• [15]Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, Blobel CP: ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 2010, 88(5):497-505.
• [16]Zhang W, Wan M, Ma L, Liu X, He J: Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer. Cell Biol Int 2013, 37(1):47-53.
• [17]Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M, Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 2006, 312(3):331-339.
• [18]Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze’ev A: Expression of L1-CAM and ADAM10 in human colon cancer cells induce metastasis. Cancer Res 2007, 67(16):7703-7712.
• [19]Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res 2011, 71(3):1071-1080.
• [20]Choi JS, Kim KH, Jeon YK, Kim SH, Jang SG, Ku JL, Park JG: Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Int J Cancer 2009, 124(6):1258-1262.
• [21]Ashktorab H, Schäffer AA, Daremipouran M, Smoot DT, Lee E, Brim H: Distinct genetic alterations in colorectal cancer. PLoS One 2010, 5(1):e8879.
• [22]Gillett CE, Springall RJ, Barnes DM, Hanby AM: Multiple tissue core arrays in histopathology research: avalidation study. J Pathol 2000, 192:549-553.
• [23]Xavier LL, Viola GG, Ferraz AC, Da Cunha C, Deonizio JM, Netto CA, Achaval M: A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Brain Res Protoc 2005, 16(1–3):58-64.
• [24]Wu X, Zou Y, He X, Yuan R, Chen Y, Lan N, Lian L, Wang F, Fan X, Zeng Y, Ke J, Wu X, Lan P: Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol 2013, 21(2):111-120.
• [25]Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher A: Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol 2006, 65:516-527.
• [26]Valkovskaya NV: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp Oncol 2008, 30:129-132.
• [27]Hernández I, Moreno JL, Zandueta C, Montuenga L, Lecanda F: Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene 2010, 29:3758-3769.
• [28]Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D: ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer 2012, 12:76.
• [29]Li Z, Liao Q, Wu Y, Liao M, Hao Y, Zhang S, Song S, Li B, Zhang YD: Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma. Pathol Oncol Res 2012, 18:657-661.
• [30]He S, Ding L, Cao Y, Li G, Deng J, Tu Y, Wang B: Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis. Med Oncol 2012, 29:2032-2037.
• [31]Li W, Ye F, Wang D, Sun X, Tong W, Lian G, Jiang J, Suo J, Zhang DY: Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer 2013, 132(8):1851-1859.